Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium

Group 1 - Merus NV (NASDAQ:MRUS) shares reached a record high following the announcement of its acquisition by Genmab AS at a 41% premium [1][2][3] - Genmab AS will acquire all outstanding shares of Merus NV at a price of $97 per share, contingent on a minimum acceptance condition of at least 80% of Merus NV's common shares [2][3] - The acquisition price represents a 41% premium over Merus NV's closing price of $68.89 on September 26 and approximately 44% over its 30-day volume-weighted average price of $67.42 [3] Group 2 - Genmab plans to finance the $8 billion transaction through a combination of cash on hand and approximately $5.5 billion of non-convertible debt financing, with a funding commitment from Morgan Stanley Senior Funding, Inc. [3]